SARC

• Initially the North American Consortium of CTOS

• 501.c.3 organization

• Incorporated November 2003

SARCMission and Vision

• Collaborate to design clinical trials• Further the knowledge regarding

diagnosis and treatment of sarcoma• Provide information to physicians,

patients and families• Utilize state of the art statistical

designEngage all appropriate and

necessary resources to cure and prevent sarcomas

Statistical Center

OperationsL. BakerD. Reinke

SARC CTOS

Institution – Multiple members of CTOSBoard of Directors – Majority from CTOS

SARC

SARC

Board of Directors

OfficersPresident Vice PresidentSecretary Treasurer

Executive CommitteeOfficers Chairpersons of standing committees

Operations Office Statistical Center

SARC Executive Committee

• L. Baker, Executive Director

• B. Maki, Deputy Executive Director

• G. Demetri

• S. Patel

• B. Benjamin (consultant)

• L. Helman (consultant)

SARC Participants

• Participant Committee– B. Maki, Chair– P. Meyers– S. George

SARC Participants– Sant Chawla, MD

• Century City Hospital– Arthur Staddon, MD

• Pennsylvania Oncology– Martin Blackstein, MD

• University of Toronto– Amir Shahlaee, MD

• University of Florida– William Tapp, MD

• UCLA– Dennis Priebat, MD

• Washington Cancer Institute– Chris Ryan, MD

• Oregon Health Science– Meg Von Mehren, MD

• Fox Chase – Kenneth Hande, MD

• Vanderbilt– James Butrynski, MD

• University of Washington

-Robert Benjamin, MDMDAnderson Cancer Center

-Robert Maki, MD, PhDMSKCC

-Scott Schuetze, MD. PhDUniversity of Michigan

-Lee Helman, MDNCI-Pediatric Branch

-Gina D’Amato, MDMoffitt Cancer Center

-Michael Fanucchi, MDEmory

-George Demetri, MDDana Farber

-David Harmon, MDMassachusetts General

-Scott Okuno, MDMayo Clinic

Pending Participants

• Charles Forscher– Cedar Sinai

• Charlotte Jacobs– Stanford

• Tom Budd– Cleveland Clinic

Foundation

• Daniel Rushing– Indiana University

• Warren Chow– City of Hope

• David Ettinger– Johns Hopkins

• Alberto Pappo– Texas Children’s

European Collaborators

• Denmark• The Netherlands• Belgium• Germany• Hungary• Switzerland• Slovakia• Poland

• Italy• France• Spain• UK• Serbia• Norway• Sweden

Common features of studies

• Multi-center– Pediatric and medical oncology

• “Novel agents” and / or novel design• Multiple subtypes of sarcoma permitted

– Specific arms for several subtypes

• Biological correlates key component of studies

• Strong biostatistical input on all studies• Web-based patient registration and

evaluation

SARC Trials

• SARC001 Gleevec in multiple subtypes

• SARC002 G v GT in metastatic STS

• SARC003 GT in bone tumors

• SARC004 Preop Gleevec in DFSP

• SARC005 Adjuvant therapy in high-risk uterine leiomyosarcoma

• SARC006 Sporadic vs nf1 MPNST

• SARC007 Perifosine in chemoresistant sarcoma

• SARC008 SMART Trial• SARC009 Dasatinib in

selected subtypes of sarcoma

• SARC010 Dasatinib in GIST

• SARC011 Lilly compound

SARC Developmental Therapeutics

• SUBCOMMITTEE CHAIR• Peter Houghton

• PRECLINICAL LABS– Experimental Therapeutics

• Lee Helman• Larry Baker

– INVIVO: • Peter Houghton( STS)• Rich Gorlick (OSTEOSARC)• Chand Khana (dogs)

• CLINICAL TRIALS– PHASE I

• Tony Tolcher

SARC Funding Sources

• US Government– DOD– DOE

• Philanthropy

• Pharma

SARC VisionSARC Vision• Build upon strengths of sarcoma programs Build upon strengths of sarcoma programs

• Expand the ability to move quickly with efficient Expand the ability to move quickly with efficient coordinationcoordination

• Develop infrastructure to facilitate collaborationDevelop infrastructure to facilitate collaboration

• Improve options for treatment and cure of Improve options for treatment and cure of sarcomasarcoma

Chawla-RosenfeldDevelopmental Therapeutics

Symposia